Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate Hexahydrate
2. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-
3. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)
4. Fostamatinib
5. Fostamatinib Disodium
6. Fostamatinib Disodium Hydrate
7. Fostamatinib Disodium Salt Hexahydrate
8. R-788 Free Acid
9. R-788 Sodium
10. R-788 Sodium Anhydrous
11. R-788 Sodium Hydrate
12. R-935788 Free Acid
13. R-935788 Sodium Anhydrous
14. R-935788 Sodium Hydrate
15. R788 Free Acid
16. R788 Sodium
17. R788 Sodium Anhydrous
18. R788 Sodium Hydrate
19. R935788 Free Acid
20. R935788 Sodium Anhydrous
21. R935788 Sodium Hydrate
22. Tavalisse
1. 1025687-58-4
2. Fostamatinib Disodium
3. R788 Disodium
4. R788 (fostamatinib) Disodium
5. R 788 Sodium
6. R935788 (fostamatinib Disodium, R788)
7. R 935788 Sodium
8. Tavalisse
9. Tamatinib Fosdium
10. X9417132k8
11. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)
12. Disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate
13. R788(fostamatinib Disodium)
14. Disodium (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2h-pyrido[3,2-b][1,4]oxazin-4(3h)-yl)methyl Dihydrogen Phosphate
15. R-935788
16. Fosd
17. Fostamatinib Sodium
18. Unii-x9417132k8
19. R788(disodium)
20. R788, Fostamatinib
21. R788 Disodium (fostamatinib)
22. R788 Sodium Anhydrous
23. Schembl3657651
24. R-788 Sodium Anhydrous
25. Dtxsid70145275
26. Ex-a2146
27. R935788 (fostamatinib Disodium)
28. R935788 - Fostamatinib Disodium
29. R935788 Sodium Anhydrous
30. R-935788 Sodium Anhydrous
31. Akos026750559
32. Ccg-270264
33. Fostamatinib Disodium Salt [mi]
34. Sb40413
35. R788(disodium); Fostamatinib Disodium
36. Ac-28433
37. As-16263
38. C71107
39. J-000725
40. J-518183
41. Q27293710
42. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate
43. 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2h-pyrido[3,2-b]-1,4-oxazi N-3(4h)-one Sodium Salt
44. Disodium,[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate
Molecular Weight | 624.4 g/mol |
---|---|
Molecular Formula | C23H24FN6Na2O9P |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 9 |
Exact Mass | 624.11218009 g/mol |
Monoisotopic Mass | 624.11218009 g/mol |
Topological Polar Surface Area | 192 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 893 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 1 | |
---|---|
Drug Name | TAVALISSE |
Active Ingredient | FOSTAMATINIB DISODIUM |
Company | RIGEL PHARMS INC (Application Number: N209299) |
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
B02BX
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-03-04
Pay. Date : 2022-01-05
DMF Number : 36629
Submission : 2022-02-04
Status : Active
Type : II
NDC Package Code : 68554-0130
Start Marketing Date : 2018-04-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registration Number : 304MF10064
Registrant's Address : St. -Peter-Strasse 25, 4020 Linz / Austria
Initial Date of Registration : 2022-04-06
Latest Date of Registration : --
GDUFA
DMF Review : Complete
Rev. Date : 2022-03-04
Pay. Date : 2022-01-05
DMF Number : 36629
Submission : 2022-02-04
Status : Active
Type : II
Fostamatinib Disodium Hexahydrate
Registration Number : 304MF10064
Registrant's Address : St. -Peter-Strasse 25, 4020 Linz / Austria
Initial Date of Registration : 2022-04-06
Latest Date of Registration : 2022-04-06
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Fostamatinib Disodium Hexahydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fostamatinib Disodium Hexahydrate, including repackagers and relabelers. The FDA regulates Fostamatinib Disodium Hexahydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fostamatinib Disodium Hexahydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fostamatinib Disodium Hexahydrate supplier is an individual or a company that provides Fostamatinib Disodium Hexahydrate active pharmaceutical ingredient (API) or Fostamatinib Disodium Hexahydrate finished formulations upon request. The Fostamatinib Disodium Hexahydrate suppliers may include Fostamatinib Disodium Hexahydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fostamatinib Disodium Hexahydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Fostamatinib Disodium Hexahydrate active pharmaceutical ingredient (API) in detail. Different forms of Fostamatinib Disodium Hexahydrate DMFs exist exist since differing nations have different regulations, such as Fostamatinib Disodium Hexahydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fostamatinib Disodium Hexahydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Fostamatinib Disodium Hexahydrate USDMF includes data on Fostamatinib Disodium Hexahydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fostamatinib Disodium Hexahydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fostamatinib Disodium Hexahydrate Drug Master File in Japan (Fostamatinib Disodium Hexahydrate JDMF) empowers Fostamatinib Disodium Hexahydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fostamatinib Disodium Hexahydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Fostamatinib Disodium Hexahydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fostamatinib Disodium Hexahydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fostamatinib Disodium Hexahydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fostamatinib Disodium Hexahydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fostamatinib Disodium Hexahydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fostamatinib Disodium Hexahydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fostamatinib Disodium Hexahydrate suppliers with NDC on PharmaCompass.
Fostamatinib Disodium Hexahydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fostamatinib Disodium Hexahydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fostamatinib Disodium Hexahydrate GMP manufacturer or Fostamatinib Disodium Hexahydrate GMP API supplier for your needs.
A Fostamatinib Disodium Hexahydrate CoA (Certificate of Analysis) is a formal document that attests to Fostamatinib Disodium Hexahydrate's compliance with Fostamatinib Disodium Hexahydrate specifications and serves as a tool for batch-level quality control.
Fostamatinib Disodium Hexahydrate CoA mostly includes findings from lab analyses of a specific batch. For each Fostamatinib Disodium Hexahydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fostamatinib Disodium Hexahydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Fostamatinib Disodium Hexahydrate EP), Fostamatinib Disodium Hexahydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fostamatinib Disodium Hexahydrate USP).
LOOKING FOR A SUPPLIER?